Related Experiment Video

Updated: Nov 22, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.2K

IGFBP2 in cancer: Pathological role and clinical significance (Review)

Lai-Feng Wei1, Xue-Fen Weng1, Xu-Chun Huang1

  • 1Department of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical College, Shantou 515041, P.R. China.

Oncology Reports
|January 8, 2021
PubMed

Insights

Insulin-like growth factor-binding protein 2 (IGFBP2) acts as an oncogene in many cancers. Elevated IGFBP2 levels are linked to tumor progression and may serve as a diagnostic and prognostic biomarker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Insulin-like growth factor-binding protein 2 (IGFBP2) is a key member of the IGFBP family.
  • IGFBP2 functions as both a secreted protein in cancer cells and a cytoplasmic signaling effector.
  • Its role as an oncogene in various human cancers has been extensively studied.

Purpose of the Study:

  • To review the multifaceted roles of IGFBP2 in cancer initiation and progression.
  • To discuss the involvement of IGFBP2 in critical oncogenic processes.
  • To explore the clinical utility of IGFBP2 as a diagnostic and prognostic biomarker.

Main Methods:

  • Literature review of current research on IGFBP2 in oncology.
  • Analysis of IGFBP2's involvement in cancer signaling pathways.
  • Evaluation of IGFBP2's expression in tumor tissues and patient serum.

Main Results:

  • IGFBP2 is significantly elevated in serum and tissues of cancer patients.
  • IGFBP2 promotes tumor proliferation, migration, invasion, angiogenesis, and epithelial-mesenchymal transition.
  • IGFBP2 often acts through insulin-like growth factor-independent pathways.
  • Aberrant IGFBP2 overexpression is implicated in various signal transduction pathways.

Conclusions:

  • IGFBP2 plays a crucial role in the initiation and progression of diverse cancers.
  • IGFBP2 interacts with key molecules in cancer signaling pathways.
  • IGFBP2 holds significant potential as a diagnostic and prognostic biomarker for malignant tumors.
  • IGFBP2 represents a potential therapeutic target for cancer management.
Keywords:
IGFBP2tumorigenesissignaling networkbiomarker

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.8K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
9.4K